• Guideline Summary
  • NGC:010502
  • 2014 Jun

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype.

  • Guideline Summary
  • NGC:010331
  • 2014 Feb

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α–based regimens.

  • Guideline Summary
  • NGC:010591
  • 2014 Aug

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.

  • Guideline Summary
  • NGC:010769
  • 2015 Jul

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing.

  • Guideline Summary
  • NGC:011000
  • 2016 Apr

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing.

  • Guideline Summary
  • NGC:009742
  • 2013 May

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.

  • Guideline Summary
  • NGC:010006
  • 2011 Aug (revised 2013 Sep)

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

  • Guideline Summary
  • NGC:010329
  • 2012 Feb (revised 2014 Apr)

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.

  • Guideline Summary
  • NGC:009743
  • 2011 Mar (reaffirmed 2013 Apr)

Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.

  • Guideline Summary
  • NGC:010701
  • 2014 Nov

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.

  • Guideline Summary
  • NGC:010590
  • 2012 Jul (revised 2014 Oct)

The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

  • Guideline Summary
  • NGC:010007
  • 2013 Sep

Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.

  • Guideline Summary
  • NGC:009587
  • 2012 Apr (reaffirmed 2014)

Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and abacavir dosing.

  • Guideline Summary
  • NGC:010330
  • 2013 Dec

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.

  • Guideline Summary
  • NGC:009588
  • 2013 Feb (reaffirmed 2015)

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.